Clinical management of anaemia pre-endstage renal failure

Clinical Medicine

Volumn 3, Issue 6, 2003, Pages 503-508

  Stevens, Paul E ^a   Flossmann, Oliver ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Cardiovascular disease; Chronic kidney disease; Erythropoietin (EPO) deficiency

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; QUALITY CONTROL; REVIEW; TARGET CELL;

EID: 0346251188     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.3-6-503     Document Type: Review

References (20)

1. The National Kidney Foundation. K/DOQI Clinical Practice Guidelines of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-S238.
2. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14(Suppl 5):1-50.
3. KDOQI clinical practice guidelines of chronic kidney disease: evaluation, classification and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 2002;39(Suppl 1]: S46-S75.
4. Hsu C, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10.
5. Hsu C, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002;13:2783-6.
6. Shulman NB, Ford CE, Hall WD, Blaufox MD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13(5 Suppl):180-93.
7. Culleton BF, Larson MG, Wilson PW, Evans JC et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56: 2214-9.
8. Levin A, Thompson CR, Ethier J, Carlisle EJ et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
9. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
10. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
11. Landray MJ, Thambyrajah, McGlynn FJ, Jones HJ et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001;38:537-46.
12. Manjunath G, Tighiouart H, Coresh J, Macleod B et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-9.
13. Gomez JM, Carrera F. What should the optimal target hemoglobin be? Review. Kidney Int 2002;61(Suppl 80):39-43.
14. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36.
15. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
16. National Service Framework for Coronary Heart Disease. London: Department of Health, March 2000. www.doh.gov.uk/nsf/coronary
17. Silverberg DS, Wexler D, Blum M, Keren G et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44.
18. Silverberg DS, Wexler D, Sheps D, Blum M etal. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
19. Silverberg DS, Wexler D, Blum M, Tchebiner JZ et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
20. Besarab A, Bolton WK, Browne JK, Egrie JC et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.